Evidence map›Paper›PMID 32839216›Full record

ArticleAntimicrobial agents and chemotherapy2020

Targeting CARD9 with Small-Molecule Therapeutics Inhibits Innate Immune Signaling and Inflammatory Response to Pneumocystis carinii β-Glucans.

Theodore J Kottom, Eva M Carmona, Andrew H Limper

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Targeting β-glucans, vital components of theFrontiers in immunology · 2023
    Review
  8. Article
  9. CARD9 Regulation and its Role in Cardiovascular Diseases.International journal of biological sciences · 2022
    Review
  10. Review
  11. CARD9 Signaling, Inflammation, and Diseases.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Theodore J KottomThoracic Diseases Research Unit, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Eva M CarmonaThoracic Diseases Research Unit, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Andrew H LimperThoracic Diseases Research Unit, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA limper.andrew@mayo.edu.ORCID 0000-0001-5671-6874
Mayo Clinic · US

Funding

Pneumocystis: Macrophage & Epithelial ActivationR01HL062150 · NHLBI · MAYO CLINIC ROCHESTER · PI ANDREW H LIMPER · 1998 to 2026
$9.2M
NHLBI NIH HHS R01 HL062150
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

beta-GlucansPneumocystisPneumocystis cariniiPneumonia, PneumocystisCARD Signaling Adaptor ProteinsHumansImmunity, Innatebeta-GlucansCARD9 protein, humanCARD Signaling Adaptor ProteinsCARD9inflammationinhibitormacrophagesPneumocystis carinii

Identifiers

PMID32839216
PMCPMC7577161
OpenAlexW3080812650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.